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Background: The aim of this study was to create a new meta-analysis method for cost-effectiveness studies using
comparative efficiency research (COMER).
Methods: We built a new score named total incremental net benefit (TINB), with inverse variance weighting of
incremental net benefits (INB). This permits determination of whether an alternative is cost-effective, given a
specific threshold (TINB > 0 test). Before validation of the model, the structure of dependence between costs and
quality-adjusted life years (QoL) was analysed using copula distributions. The goodness-of-fit of a Spanish
prospective observational study (n = 498) was analysed using the Independent, Gaussian, T, Gumbel, Clayton, Frank and
Placket copulas. Validation was carried out by simulating a copula distribution with log-normal distribution for costs
and gamma distribution for disutilities. Hypothetical cohorts were created by varying the sample size (n: 15–500) and
assuming three scenarios (1-cost-effective; 2-non-cost-effective; 3-dominant). The COMER result was compared to the
theoretical result according to the incremental cost-effectiveness ratio (ICER) and the INB, assuming a margin of error of
2,000 and 500 monetary units, respectively.
Results: The Frank copula with positive dependence (−0.4279) showed a goodness-of-fit sufficient to represent costs
and QoL (p-values 0.524 and 0.808). The theoretical INB was within the 95% confidence interval of the TINB, based on 15
individuals with a probability > 80% for scenarios 1 and 2, and > 90% for scenario 3. The TINB > 0 test with 15 individuals
showed p-values of 0.0105 (SD: 0.0411) for scenario 1, 0.613 (SD: 0.265) for scenario 2 and < 0.0001 for scenario 3.
Conclusions: COMER is a valid tool for combining cost-effectiveness studies and may be of use to health decision
makers.
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Economic evaluation of health technologies (EEHT) has
become a first-order health policy decision making tool
at the European level. EEHT allows both the economic
and clinical value of technologies (drugs, devices, health
programs, etc.) to be evaluated [1] and, when used for
the allocation of health resources, allows decision-
makers to make informed decisions on specific problems
by combining the probabilities of all possible outcomes
and the health benefits assigned to each of them [2,3].* Correspondence: ccrespo@ub.edu
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unless otherwise stated.In the last decade, there has been a rise in EEHT, as
reflected by the large amount of cost-effectiveness stud-
ies [4,5] and the interest in the technological advances
generated by their results. Although cost-effectiveness
analyses (CEA) have improved due to the development
of methods of synthesizing evidence, systematic revisions
and direct, indirect and mixed meta-analyses [6,7], there
is still no consensual method for carrying out meta-
analyses of CEA. Proposed methods range from mere
qualitative review of CEA [8,9] to the categorization of
CEA according to whether the costs are higher, the same
or lower and whether the effects are better, the same or
poorer, in order to assess how many CEA there are in
each category [10]. We suggest that the method for
meta-analyses of CEA proposed here, which is known as
COMparative Efficiency Research (COMER), and whichThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sent reality more closely and allow more evidence-based
decision making. As for any meta-analysis, the validity of
the COMER method will depend on systematic review
of the types of studies supporting the data, the popula-
tions assessed and the variability or levels of consistency
between centres and/or studies.
Although meta-analyses usually use aggregate study
data, recent research has shown that the use of individual-
level data or individual- and aggregate-level data, allows
for a better estimate of variability [11,12]. Therefore, the
COMER method should be able to use both individual
and aggregate data, although it remains difficult to obtain
original data from clinical studies for use by researchers
other than the original authors [13].
The aim of this study was to create a method of CEA
meta-analysis based on either individual or aggregate
data through the generation of a multivariate distribu-
tion function which allows the dependence between
costs and effects to be modelled. This mathematical de-
pendence is called copula.
Methods
Cost-effectiveness studies compare the efficiency of ther-
apies evaluated using the incremental cost-effectiveness
ratio (ICER), where the numerator is the difference be-
tween the estimated cost of the new treatment and that
of the reference treatment and the denominator esti-
mates the effectiveness gained by the new treatment




where 1 and 2 correspond to the new treatment and the
reference treatment, respectively.
Thus, when the therapy being assessed is more expen-
sive than the reference treatment, and is also less effect-
ive, the new treatment is dominated. When the
treatment is more effective than the reference treatment,
and also less expensive, the new treatment is dominant
over the reference treatment. In the remaining cases, the
ICER must be compared with the willingness to pay (k)
to assess whether the new treatment is cost-effective
(ICER < = k) or not cost-effective (ICER > k) [1,2]. The
choice of the threshold of efficiency remains an unre-
solved issue in many health systems. Theoretically, the
threshold of efficiency should be related to the value that
society accords to a health outcome in, for example, life
years gained, depending on the available resources [1,2].
One limitation of the ICER is that, as it is a ratio, the
expected value of the ICER represents the difference in
the expected cost divided by the difference in the ex-
pected effectiveness. Therefore, the main difficulty in
making inferences from cost-effectiveness studies is thatthe random variable obtained is not necessarily normal
or symmetric [14]. However, even when cost and effect-
iveness data are distributed normally, there is no guaran-
tee that the ratio between them will also behave
normally and, ultimately, it is not possible to calculate
the confidence intervals (CI). Thus, there is a need to
use alternative methods, such as bootstrapping or incre-
mental net benefits (INB) for this purpose [15].
Therefore, the COMER methodology, both for individ-
ual and aggregate data, consists of estimating the total
incremental net benefit (TINB) according to the INB of
the studies included weighted by the inverse of the vari-
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¼ k 
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X
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Where s is the number of the study and 1 and 2 the
new treatment and reference treatment, respectively:
and
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and the variance is:






ω2s  var INBsð Þ
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According to the central limit theorem, the INB is
asymptotically normal [15] and the TINB is also
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known, and the probability of the TINB being < 0 can be
calculated. Therefore, the decision criterion will be that
the new treatment is cost-effective for the established
threshold if the probability is lower than 5% (Table 1).
Equivalently,
H0 : TINB≤0
H1 : TINB > 0
with
Zexp ¼ TINB − 0ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var TINBð Þp ∼ N 0; 1ð Þ where p − value
¼ 1 − P Z ≤ Zexp
 
Validation of the method
The costs and effects of individual patients were mod-
elled for marginal distributions to illustrate the COMER
method. The use of the copula distribution, which per-
mits the joint distribution of costs and effects to be ob-
tained, has been suggested [16], since the dependence
between costs and effects does not have to be linear. In
this way, a cost and effect dependence structure is
obtained through the copula and their univariate
behaviour.
The process carried out consisted of:
 Identifying the copula: the joint distribution that
best fits the costs and effects.
 Creating a simulated cohort under the marginal and
joint distribution for each alternative compared.
 COMER estimation.
 Method validation.
Identification of marginal distributions and copula
Copulas are bivariate distributions that provide dependent
structures for two statistical variables, with any type of
univariate distribution [17-19]. In its construction, a C(u,v)
copula is a multivariate distribution function defined fromTable 1 Summary of COMER outcomes
Study
Alternative 1 Alternative 2
ICER
Costs Effects Costs Effects
1 c11 e11 c12 e12 ICER
2 c21 e21 c22 e22 ICER








Var INBsð Þp 
ICER: Incremental Cost-effectiveness Ratio; INB: Incremental Net Benefit.
TINB: Total Incremental Net Benefit.U and V random variables with uniform distribution in the
interval [0,1], which verifies the following properties:
1. C(u, 0) = 0 = C(0, v)
2. C(u, 1) = u and C(1, v) = v
3. For u1, u2, v1, v2 in [0, 1] so that u1 ≤ u2 and v1 ≤ v2,
C(u2, v2) −C(u2, v1) −C(u1, v2) + C(u1, v1) ≥ 0.
Since the relationship between random variables is not
based on the distribution, but rather constructed from
mathematical structures between random variables, de-
pendence can be evaluated using non-parametric correl-
ation statistics (Spearman’s ρs and Kendall’s τ), which are
independent on marginal distributions.
Copula distributions are little used in health econom-
ics, and are mainly applied to specify the distribution of
regression models with more than one dependent vari-
able [20-23]. We used copulas to describe the depend-
ence structure of cost-effect random variables, allowing
random generation of a patient cohort under such a
distribution in order to make different simulations. By
applying copulas to EEHT, the joint distribution of each
treatment can be simulated, since Cj(cij,eij) is a copula
for treatment j, where costs (c) and effects (e) are
known for each patient i. In addition, Sklar’s theorem
[24] shows that, given a copula (the joint distribution),
the copula can be reconstructed through the marginal
theoretical or empirical inverse distribution function, ac-
cording to the specific case. However, recent studies show
that there is no justification for the claim that a specific
copula may be the most appropriate for the combination
of costs and effects, not even when costs are broken down
into direct and indirect costs, or if effects are represented
by the following measurements: therapeutic success, life
years, or quality-adjusted life years (QALY) [25].
To create a hypothetical population to test the validity
of the COMER methodology, we used data from a Spanish
prospective observational study of patients with allergic
rhinitis (n = 498) with direct costs (c) and mean utilities
from the SF-12v1 (e) [26]. The study served to obtain a
copula structure which, by adding some theoretical mar-
ginal distributions, allowed the generation of a hypotheticalINB (variance) INB <0 (%)* Weight (%)
1 INB1 (Var(INB1)) P(x1<0) ω1
2 INB2 (Var(INB2)) P(x2<0) ω2
3 INB3 (Var(INB3)) P(x3<0) ω3
S TINB =Σ ωs *INBs, (Var(TINB)) P(TINB<0) Σ ωs=1
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The empirical copula was compared to the parametric esti-
mate of the potential copula (Additional file 1) to evaluate
the goodness of fit of the data with the theoretical copulas
[27]. The copula bound to evaluate the goodness of fit was
developed using the inversion of Kendall’s τ. The p-value
of the test was calculated by simulation of size-100 boot-
strap, due to the lack of an analytical construction.
The following copulas were evaluated [19,25,28]:
Independent copula: this can be generated automat-
ically since, given U and V random variables, the joint
distribution function is C0(u, v) = u * v. Thus, the as-
sociation between this copula and some data indicates
the stochastic independence of U and V; equivalently,
the absence of structure.
Gaussian copula: this is defined as G∅(u, v) =
Nρ(Φ
− 1(u),Φ− 1(v)) where Nρ(x, y) is the normal distribu-
tion function of parameters x: mean and y: the standard
deviation, Φ− 1(x) is the marginal distribution func-
tion N(0,1) and ρ is Pearson’s correlation coefficient. The
Gaussian copula is still a multivariate normal distribution.
T copula: this is derived from the Student’s t multi-
variate distribution and is defined as Tθ;ρ u; vð Þ ¼






1þ u2 þ v2 − 2ρuvð Þ= θ 1 − ρ2ð Þð Þð Þ− θþ2ð Þ=2
where |ρ| < 1, θ > 0. This copula shows a similar struc-
ture to the Gaussian copula, but presents tail depend-
ence, points (0,1) and (1,0). One of its qualities is that
it includes the Gaussian copula when θ→∞.
Gumbel copula: this allows a positive dependence
structure to be modelled, region (1,1), and is defined as





[1,∞]. When θ = 1 it is equivalent to the independent
copula and when θ→∞ it behaves as a comonotonic
copula (min(u,v)). Thus, the behaviour of the Gumbel
copula is an interpolation between the independent cop-
ula and the copula of perfect positive dependence.
Clayton copula: this is defined as COθ u; vð Þ ¼
u−θ þ v−θ−1 −1θ where θ > 0. Like the Gumbel copula,
this copula is an interpolation but lies between the inde-
pendent copula and the perfect negative dependence
(point (0,0)).
Frank Copula: this has the quality of showing symmet-
ric dependencies and not showing dependence at points
(0,0) and (1,1). It is defined as Fθ u; vð Þ ¼ −1θ ln
1 þ exp −θuð Þ − 1ð Þ exp −θvð Þ − 1ð Þexp −θð Þ−1
 
where θ ∈ℝ \{0}.
Plackett copula: this is defined as Pθ u; vð Þ ¼
1 þ θ − 1ð Þ u þ vð Þ −
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 þ θ − 1ð Þ u þ vð Þð Þ2 − 4uvθ θ − 1ð Þ
p
2 θ − 1ð Þwhere θ ≥ 0. This structure shows both positive and
negative maximum dependence in function of param-
eter θ.
Creation of cohorts
Once the joint distribution was known, some theoret-
ical marginal distributions were associated. To simu-
late costs, a lognormal distribution was associated, and to
simulate life quality, a gamma distribution was associated
(disutilities), with respect to a baseline quality of life
(0.9 utility) [14] (Table 2). For the two alternatives, the
same copula and the same randomization (bivariate uni-
forms [0,1]) were used. This ensured covariance and cor-
relation between the values generated for the costs and
effects. Different random samples per cohort were cre-
ated with sample sizes between 15 and 500 individuals
for each alternative. Individuals in the simulated cohort
were randomly assigned to the studies. To ensure that
there was a minimum variability per study, the random
assignation was conditioned to ensure that, for each
study, there were at least 3 individuals.
The COMER methodology was applied to the simu-
lated data for each alternative. For each alternative the
mean costs, mean effectiveness, differential variance in
costs, differential variance in effects and covariance be-
tween the differences in costs and effects, and the INB
were estimated, setting an efficiency threshold (k = 30,000
monetary units per QALY gained). For example, of a sam-
ple of 15 individuals, the seven first could be assigned to
study 1, the following five to study 2, and the remaining
three to study 3, and the COMER methodology applied
(Additional file 2).
For each sample size generated, 500 replications were
made, entailing 25,000 meta-analyses for each scenario, thus
allowing the number of the times the methodology agreed
with reality to be validated. A 2,000-monetary-unit/QALY-
tolerance was assumed to calculate the ICER, and a
500-monetary-unit-tolerance was assumed for the TINB.
Additionally, we estimated the minimum sample size re-
quired to obtain an adjusted estimate with a probabil-
ity >70% and when simulations converged to the original
Kendall’s τ.
The following are the scenarios evaluated by modifying
the marginal distribution parameters (Table 2):
1. The second alternative is cost-effective.
2. The second alternative is more costly and more
effective, although the ICER is above the willingness
to pay threshold.
3. The second alternative is dominant.
All the possibilities are covered by these scenarios
since the remaining potential outcomes derived from
an EEHT which have not explicitly been evaluated are
Table 2 Simulated scenarios
Scenario 1: Cost-effective
CONTROL ACTIVE
Cost Lognormal (6.214608, 0.75) Lognormal (6.907755, 0.75)
Effect 0.9-Gamma (6.25, 0.024) 0.9-Gamma (2, 0.05)




Cost Lognormal (6.214608, 0.75) Lognormal(6.214608, 0.75)
Effect 0.9-Gamma (6.25, 0.024) 0.9-Gamma (4.5, 0.03)




Cost Lognormal (6.907755, 0.75) Lognormal (6.214608, 0.75)
Effect 0.9-Gamma (6.25, 0.024) 0.9-Gamma (2, 0.05)
ICER −13,247.85 = (662.39 – 1,324.78)/(0.8-0.75)
INB* 2,162.39
ICER: Incremental Cost-effectiveness Ratio; INB: Incremental Net Benefit.
*k=30,000.
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second alternative instead of the first.
The analysis was made using the R 3.0.1 statistical
package (Additional file 3). In addition, the COMER
method is included as an Excel file in the supplementary
materials (Additional file 4).
Results
Comparison of the copulas used with the real costs and
effects data showed p-values between 0.075 and 0.191
for the independent distribution, 0.443 and 0.769 for
the Gaussian copula, 0.309 and 0.633 for the T copula,
0.004 and 0.034 for the Gumbel copula, 0.242 and
0.526 for the Clayton copula, 0.524 and 0.808 for the
Frank copula and 0.531 and 0.808 for the Plackett cop-
ula (Table 3).Table 3 Goodness-of-fit of p values (100 times)
Minimum 1st quartile Me
Independent 0.075 0.105 0
Gaussian 0.443 0.558 0
T 0.309 0.457 0
Gumbel 0.004 0.011 0
Clayton 0.242 0.355 0
Frank 0.524 0.663 0
Plackett 0.531 0.668 0Therefore, both the Frank and Plackett copulas were
candidates to be the copula for the distribution of the
simulated cohort. We opted for the Frank copula, which
showed a value of −0.4279 (p-value: 0.128), indicating a
positive dependence between costs and effects (Figure 1).
Evaluation of the convergence from the empirical to the
theoretical Kendall’s τ showed a range between −0.505
and 0.543 for 15 simulated individuals (mean: 0.029; SD:
0.192), between −0.135 and 0.228 for 115 individuals
(mean: 0.046; SD: 0.062) and between −0.059 and 0.130








.71In the cost-effectiveness scenario it was observed
that, starting from a sample size of 75 individuals per








Figure 1 Adjusted Copula (Frank Copula) vs. Empirical Copula.
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number of simulated individuals was increased,
the adjustment increased with probabilities > 90%.
Comparison of the INB with the individual data
and the TINB showed a minimum of 175, 115
and 75 individuals were necessary to obtain a
probability greater than 70%, when tolerances
of 6%, 9% and 12%, respectively, were assumed.
However, the INB was within the CI of the TINB
with a probability > 85% for samples of > 15
individuals and > 90% for samples > 25 individuals.
The same happened when the CI of the TINB for
each meta-analysis was compared with the theor-
etical value of the INB. (+80% for 15+ individuals
and +90% for 25+ individuals) (Figure 2A).
With respect to the probability of alternative 2
being cost-effective, for the sample size of 15
individuals, the p-value was 0.0105 (SD: 0.0411),
for 115 individuals it was 0.015 (SD: 0.0214) and
for 415 individuals it was 0.0165 (SD: 0.0128).
Thus, for the meta-analyses obtained, alternative
2 was cost-effective.
2. Non-cost-effective scenario
The ICER reached values > 70% within the
tolerance, from 400 individuals upwards.
Because the denominator of the ICER had a
mean difference of 0.01 QALYs, the ICER
showed values between 19,840 and 103,436 for
n: 15. This meant that, in 7% of the simulations
with n: 15 and in 1% of those with n:35,the ICER
was inferior to the willingness-to-pay, and was
thus cost-effective. However, the probability of
the INB being within the tolerance (500 monetary
units) was > 95% for any sample size.
Comparison of the INB with the individual data
with respect to the 95% CI of the TINB showed a
probability of 85% for samples > 15 individuals.
The same occurred when the 95% CI of the TINBfor each meta-analysis was compared with the
theoretical value of the INB (+80% for 15+ individ-
uals and +90% for 25+ individuals) (Figure 2B).
The mean difference between the mean TINB and
the theoretical value showed a range of 15 to 121
monetary units.
With respect to the probability of alternative 2
being cost-effective, for the sample size of 15
individuals, the p-value was 0.613 (SD: 0.265),
for 115 individuals it was 0.709 (SD: 0.123) and
for 415 individuals it was 0.729 (SD: 0.072). Thus,
for the meta-analyses obtained, the outcome
showed that alternative 2 was not cost-effective.
3. Dominant scenario
The ICER reached values > 70% within the
tolerance, from 35 individuals upwards, while the
INB reached these values from 15 individuals
upwards. Furthermore, when comparing the INB
with the individual data and the theoretical INB
with a 6% tolerance, a probability > 70% was
obtained from 35 individuals upwards.
When the INB of the individual data or the
theoretical INB was within the CI, probabilities >
90% were observed for any sample size
(Figure 2C). Regarding the probability of
alternative 2 being cost-effective, scenario 3
showed p-values < 0.0001 for any sample size.
Discussion
EEHT are a set of tools which aim to examine the short
and long-term consequences of using health technologies
on individuals and on society. Since there are numerous
alternatives for allocating those resources, EEHT tries to
make relevant information from the efficiency perspective
available to health decision makers, understanding effi-
ciency as the maximization of health gains obtained from
the limited resources available. The application of COMER
in decision-making may allow decision-makers to move
Figure 2 Boxplot of TINB convergence. A: Cost-effective scenario;
B: Non-cost-effective scenario; C: Dominant scenario.
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based on evidence, understanding evidence within a com-
prehensive framework where both clinical and economic
evidence are compatible. COMER may be applied both in
studies where individual level data or aggregate level data
are available, always provided the covariance matrix of the
difference between costs and effects, the mean cost and
the mean effects of each alternative are available. When
there is access to individual data from clinical studies, these
measurement can be obtained through bootstrapping
[29-31], and in the case of economic evaluation models,
they can be obtained from the Monte Carlo simulation
[14]. The advantage of bootstrapping is that it is a non-
parametric method which does not presuppose any distri-
bution and is based on studying the sample as if it were
the population, through resampling [30].
We believe that the fact that the simulated individuals
were only assigned to 3 studies did not influence the re-
sults. Although many meta-analyses agglutinate more
than 3 studies, the number of studies used was the mini-
mum required to enable evaluation of the generalizationof the results. In addition, in the assignation of individ-
uals per study we forced the assignation of three or
more individuals to avoid studies with minimum or null
variability. Although, in reality it is unusual to find stud-
ies with 3 cases, analysis of very-small samples allows a
small number of individuals to be assigned, thus generat-
ing greater heterogeneity between studies, as occurs in
reality. However, the analysis with small simple sizes
showed, as expected, greater divergence in the results
obtained using the ICER and the TINB. Likewise, using
two theoretical distributions such as the lognormal for
costs and the gamma for disutilities is sufficient to valid-
ate the method. Furthermore, since approximation by
copulas is independent of marginal distributions, and be-
cause typical theoretical distributions were selected to
simulate the uncertainty of the costs and disutilities, we
believe that the outcome is not biased by this decision.
However, any interpretation of the COMER method-
ology must take into consideration the field in which it
has been implemented and validated. In addition, the
meta-analysis constructed has fixed effects (inverse vari-
ance weighting), which means it must be assumed that
the studies are homogenous. This assumption does not
necessarily occur in reality, and even though, to validate
the method, different sample sizes and high levels of
variance (e.g., a coefficient of variation for the costs >1)
were used to generate greater heterogeneity in the study
data, this should be taken into account when interpret-
ing the results. Future studies should use the COMER
methodology to develop a method to adjust the diver-
gences in the homogeneity of the populations evaluated,
similar to that carried out for meta-regressions.
A potential limitation to applying the COMER method
is that health systems in different countries can generate
different resource uses and, hence, different total costs.
For this reason, the transfer of economic evaluations
must be assessed and costs must be homogenized before
using this method [32-34]. When using studies from dif-
ferent countries with potentially-similar cost structures,
the currencies must be homogenized to US dollar equiv-
alents and costs must be updated to the same year, as is
done in comparisons made by the World Health
Organization [35], the OECD [36] or the IMF [37].
Some authors suggest that a separate cost and effective-
ness meta-analysis is sufficient to make an appropriate
value judgment [38], while other suggest assessment of
the results of the costs and marginal effects of CEA in
order to evaluate the worth of a new treatment [10]. How-
ever, we believe that the COMER method has potential
applications, even for teams with limited resources. Mere
systematic review and meta-analysis, separate from eco-
nomic evaluation studies, are not an EEHT per se, as they
could lead decision makers to draw the wrong conclusion
due to the impossibility of balancing global costs and
Crespo et al. BMC Medical Research Methodology 2014, 14:139 Page 8 of 9
http://www.biomedcentral.com/1471-2288/14/139effects and measuring additional value. EEHT should
be accompanied by a fuller meta-analysis such as the pro-
posed COMER method, although a full, new EEHT might
be necessary if sufficient information were not obtained
by the COMER method.Conclusions
Systematic review of economic analyses requires methods
to synthesize and interpret the results of multiple analyses.
The COMER methodology is a valid option for the ana-
lysis of both individual and aggregate data and may allow
decision-makers to better understand the added value of
new therapeutic alternatives by synthesizing all available
evidence. The COMER methodology opens the way to
further research of this type of meta-analysis with two var-
iables having a known dependence structure [16], both
from a frequentist and from a Bayesian perspective [39].Additional files
Additional file 1: Copula distributions and associated correlation.
Additional file 2: Example of the COMER with a sample size of 15
(scenario cost-effective).
Additional file 3: Script COMER function in R.
Additional file 4: Comparative efficiency research (COMER)
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